Bavarian Nordic Strengthens its Commercial Organisation and Updates on Pipeline Progress
2007 OCT 1 -- Bavarian Nordic will establish a new separate sales- and marketing function in order to strengthen the company's commercial activities and increase the sales promotion for its third generation smallpox vaccine, IMVAMUNE(R) and future vaccines, including HIV and cancer vaccines. The commercial function will, besides intensifying the sales promotion of IMVAMUNE(R), ensure that the company's research and development is going in a commercial way to a still higher extent, and that necessary market knowledge at an early stage is integrated in the decision-making processes within clinical development. Within the latest years Bavarian Nordic has used many resources on obtaining the RFP-3 order from the U.S. government. The production facility in Kvistgaard is completed, and the company has advanced its clinical development of the IMVAMUNE(R) smallpox vaccine. With a strong patent position on the company's MVA technology, Bavarian Nordic is ready to fully exploit the commercial options worldwide. The company sees a great potential in a market for IMVAMUNE(R) outside the U.S. In order to cultivate this market, Bavarian Nordic will strenghten its effort towards potential customers and partners. To lead this new commercial function, Bavarian Nordic will employ an Executive Vice President Commercial Affairs, who will join the Corporate Management group and refer to Anders Hedegaard, CEO. The company expects to appoint a person for this position within the end of 2007. Furthermore a number of other people will be employed to strengthen the sales and marketing work. Status on development programmes IMVAMUNE(R) - smallpox vaccine The RFP-3 base contract with a total value of USD 500 million covers a development contract followed by delivery contract. Keywords: Bavarian Nordic GmbH, Biotechnology, Biotechnology Business, Biotechnology Company, Immunization, Patents, Smallpox Vaccines, Vaccination, Smallpox Vaccine, Bavarian Nordic A/S. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
